Cho Tomoki, Uchida Keiji, Yasuda Shota, Onakatomi Yasuko, Fushimi Kenichi, Kaneko Shotaro, Minami Tomoyuki, Saito Aya
Department of Cardiovascular Center, Yokohama City University Medical Center, 4-57 Urafunecho, Minami-Ku, Yokohama, 232-0024, Japan.
Department of Surgery, Yokohama City University, Yokohama, Japan.
J Cardiothorac Surg. 2025 Apr 24;20(1):220. doi: 10.1186/s13019-025-03417-7.
We reviewed the treatment outcomes for aortic arch aneurysms in elderly patients aged > 80 years, and discussed the risk factors for each technique.
Octogenarians who underwent aortic arch aneurysm repair between 2007 and 2021 were included. Fifty-four patients (23 in the total arch replacement [TAR] group and 31 in the thoracic endovascular aortic repair [TEVAR] group) were included in the study. The early- and mid-term outcomes and risk factors for all-cause mortality were examined in each group. To examine timely surgical outcomes, cases of true aneurysms were included, whereas dissected aneurysms and emergency cases due to rupture or other causes were excluded.
No significant differences in 30-day mortality (0% in the TAR group and 5.4% in the TEVAR group) and in-hospital mortality (7.7% in the TAR group and 8.1% in the TEVAR group) were observed between the two groups. The survival rates at 5 years were 82% and 65% in the TAR and TEVAR groups, respectively, without significant difference. The aorta-related averted mortality was 91% and 81% in the TAR and TEVAR groups, respectively, without significant difference. No significant difference in the freedom from aortic events was also observed between the two groups. Previous ischemic heart disease was a significant risk factor for all-cause mortality in the TAR group. No significant risk factors were identified in this group.
The choice of procedure was reasonable when considering frailty. Endovascular repair may be a good treatment option for patients with a history of ischemic heart disease.
我们回顾了年龄大于80岁的老年患者主动脉弓动脉瘤的治疗结果,并讨论了每种技术的风险因素。
纳入2007年至2021年间接受主动脉弓动脉瘤修复术的八旬老人。本研究共纳入54例患者(全弓置换术[TAR]组23例,胸主动脉腔内修复术[TEVAR]组31例)。对每组的早期和中期结果以及全因死亡的风险因素进行了检查。为了检查及时的手术结果,纳入了真性动脉瘤病例,而排除了夹层动脉瘤以及因破裂或其他原因导致的急诊病例。
两组之间在30天死亡率(TAR组为0%,TEVAR组为5.4%)和住院死亡率(TAR组为7.7%,TEVAR组为8.1%)方面未观察到显著差异。TAR组和TEVAR组的5年生存率分别为82%和65%,无显著差异。TAR组和TEVAR组与主动脉相关的避免死亡率分别为91%和81%,无显著差异。两组之间在无主动脉事件方面也未观察到显著差异。既往缺血性心脏病是TAR组全因死亡的显著风险因素。该组未发现其他显著风险因素。
在考虑身体虚弱情况时,手术方式的选择是合理的。血管腔内修复术可能是有缺血性心脏病病史患者的良好治疗选择。